Cytokinetics, Inc. (CYTK)

[pzottkpz]

looking strong! $30

wish I was told to buy it instead of short it

left a lot of money on the table with this one

[MiamiGent]

CYTK Only 28 received the drug candidate. Phase 3 would not even be until next year. This company burns money like Biden.
Be patient with your short.

MG

[MiamiGent]

CYTK --Goldman Sachs Adjusts Cytokinetics PT to $26 From $21, Maintains Neutral Rating
BY MT Newswires — 11:22 AM ET 07/20/2021
11:22 AM EDT, 07/20/2021

SP currently over $30

[pzottkpz]

HOD!

wow. this keeps going up!

the visual is insane!
look at that chart!

[MiamiGent]

CYTK For those who are more visual, here's what waiting for the CYTK pullback looks like.

https://www.bing.com/images/search?view=detailV2&ccid=%2b0KDwaBt&id=6F59A9C3D2921BE19200BD099C69677694037F6C&thid=OIP.-0KDwaBtfHKpP7i_AcRYlAHaIH&mediaurl=https%3a%2f%2fstarecat.com%2fcontent%2fwp-content%2fuploads%2fbears-waiting-for-the-stock-market-to-pullback.jpg&cdnurl=https%3a%2f%2fth.bing.com%2fth%2fid%2fR.fb4283c1a06d7c72a93fb8bf01c45894%3frik%3dbH8DlHZnaZwJvQ%26pid%3dImgRaw&exph=805&expw=735&q=pictures+of+bears+waiting+for+the+market+pullback&simid=608005968660614079&FORM=IRPRST&ck=5923CD08BE7B71E0E0CBDEC4EF3DA87C&selectedIndex=0&idpp=overlayview&ajaxhist=0&ajaxserp=0

[MiamiGent]

CYTK Added to last night's AH short. New short average is 28.07

Manipulated up now in order to dump $200M Offering announced 4PM yesterday, from an existing shelf. And prolly another $35M overage.

Grade up a short, if inclined.

Will require a little patience

MG

https://stockcharts.com/h-sc/ui?s=CYTK

[MiamiGent]

CYTK Completely manipulated up today to unload $200M in shares and prolly another $30M. See yesterday's dilution announcement.
Don't go long here, imo.
Should drift down as MM peels shares into the OS, if not outright collapse.
Short is way, imo.
MG

[Pedro2004]

Now, yesterday's trading makes sense.

Thanks for the info.

[make it happen]

Another $200,000,000 million of dilution

[Pedro2004]

Too many profit takers today.

[make it happen]

Added $700,000,000 MILLION on phase 2 while hemorrhaging money and in huge debt. Book Value $0.95 VS. $28.00

[make it happen]

Phase 2, burning huge capital & debt.

Long way to go

Income Statement
Revenue Per Share $0.87
Gross Profit. -41.12M...
EBITDA -102.23M
Net Income Avi to Common -134.99M
Diluted EPS -2.00

Balance Sheet
Total Debt $228.32M...
Book Value Per Share 0.95

Cash Flow Statement
Levered Free Cash Flow -75.76M...

[make it happen]

Book Value Per Share $0.95
Revenue per share $0.87

$228,320,000 million in debt

Huge triple digit negative Profitability in all aspects. -230.55% & -177.95%

Profitability
Profit Margin -230.55%
Operating Margin (ttm) -177.95%

Management Effectiveness
Return on Assets (ttm) -15.62%
Return on Equity (ttm) -1,219.69%

Income Statement
Revenue (ttm) 58.55M
Revenue Per Share (ttm) 0.87
Gross Profit (ttm) -41.12M
EBITDA -102.23M
Net Income Avi to Common (ttm) -134.99M
Diluted EPS (ttm) -2.00

Balance Sheet
Total Cash (mrq) 425.58M
Total Cash Per Share (mrq) 5.93
Total Debt (mrq) 228.32M
Total Debt/Equity (mrq) 336.52
Current Ratio (mrq) 12.05
Book Value Per Share (mrq) 0.95

Cash Flow Statement
Operating Cash Flow (ttm) 9.56M
Levered Free Cash Flow (ttm) -75.76M

[HzSean]

Recovery starting now back up

[HzSean]

Buy in now and enjoy the ride back up! $

[ClayTrader]

* * $CYTK Video Chart 10-08-2020 * *

Link to Video - click here to watch the technical chart video

[conix]

What is their Cash on Hand?

Key question.

[jacksira]

41 Sells by the insiders in the past 6 months maybe they know something?

SEC Transactions Last 6 Months Buy / Sell
Buys 0
Sells 41
Total 41
Shares Bought 0
Sold 395,109
Gross 395,109
Net -395,109

[HzSean]

The time to buy is now. Everyone goes through positive and negative test results. Through failure you find your best success and in time that exactly what we will see in this stock. Good luck im loading.

[whytestocks]

Breaking News: $CYTK Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2020 it granted stock options to purchase an aggregate of 10,950 shares of common stock to three new employees whose employment commenced in Septemb...

Find out more CYTK - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

[whytestocks]

Breaking News: $CYTK Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020

Real-World Population Representative of P atients Enrolled in GALACTIC-HF I ndicate a H igh- N eed, H igh- R isk P opulation with Heart Failure New Results from COSMIC-HF Show Treatment with Omecamtiv Mecarbil Ass...

In case you are interested CYTK - Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020

[ClayTrader]

* * $CYTK Video Chart 10-05-2020 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

Breaking News: $CYTK Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals

Grant s Suppor t Community Engagement for Patient Advocacy Organization s Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 1 3 th , 2020 SOUTH SAN FRANCISCO, Calif., Sep...

In case you are interested CYTK - Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals

[whytestocks]

News: $CYTK Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today's Virtual Investor & Analyst Day

Topline Results from GALACTIC-HF,  Phase 3 Clinical Trial of Omecamtiv Mecarbil, Cardiac Myosin Activator, Expected in Q4 Licensing Collaboration and Royalty Monetization Deals with Xi Jing Pharmaceuticals and RTW Investments Accelerate and Expand Development of CK-3773274, Nex...

Got this from CYTK - Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today's Virtual Investor & Analyst Day

[whytestocks]

News: $CYTK Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

$250 Million in Committed Capital to Cytokinetics; Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing Pharmaceuticals to Develop & Commercialize in China RTW Provides Access to Capital to Cytokinetics to Fund Global Developmen...

In case you are interested CYTK - Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

[ClayTrader]

* * $CYTK Video Chart 05-11-2020 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $CYTK Video Chart 12-13-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $CYTK Video Chart 11-19-19 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

News: $CYTK Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting

Trial Did Not Meet Statistical Significance for Primary Efficacy Analysis Patients on All Doses of Reldesemtiv Declined Less Than Patients on Placebo for SVC and ALSFRS-R, With Clinically Meaningful Differences Emerging Over Time Early Terminations and Serious Adverse Ev...

Read the whole news https://marketwirenews.com/news-releases/cytokinetics-announces-results-of-fortitude-als-a-phase-2-clinical-trial-of-reldesemtiv-in-patients-with-als-presented-at-american-academy-of-neurology-annual-meeting-8118356.html

[whytestocks]

News: $CYTK Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, March 20, 2019 (GLOBE NEWSWIRE) -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first pl...

In case you are interested https://marketwirenews.com/news-releases/amgen-cytokinetics-and-servier-announce-continuation-of-galactic-hf-following-planned-interim-analysis-7858294.html

[whytestocks]

News: $CYTK Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

THOUSAND OAKS, Calif. , and SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently comp...

Find out more https://marketwirenews.com/news-releases/amgen-cytokinetics-and-servier-announce-continuation-of-galactic-hf-following-planned-interim-analysis-7858292.html

[whytestocks]

News: $CYTK Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that the Six Minute Walk Test (6MWT) is an acceptable primary efficacy endpoint for a poten...

Read the whole news https://marketwirenews.com/news-releases/cytokinetics-announces-receipt-of-fda-feedback-regarding-reldesemtiv-in-patients-with-sma-7414652.html

[ConstitutionNow]

Anyone following this? Seems to be some pretty impressive drugs in their portfolio!

[bigarow]

[ClayTrader]

* * $CYTK Video Chart 11-21-17 * *

Link to Video - click here to watch the technical chart video

[H2R]

I'm glad you are already making money back :)

Sorry this did not work. It would have been great for ALS patients and for Longs. Too much happening at work today, I'll have to think about the next investment. Maybe not in biotech, I've been burned a couple times lately.

Best of luck Sugarshaker!!!

[Sugarshaker]

Thanks H2R for all help sold out and bought amazon already making money back.

[H2R]

No I did not. I saw the price drop and did not do a damn thing, just waited like a lamb to be slaughtered. Arggg.

Sure hope my other positions will be better. but not a good day.

best of luck in your investments North40000!

[north40000]

You had some foresight[prescience?] a little over a month ago of what could be a portent with observation of share price drop....we saw the same share price drop, and like you, did nothing until we saw today(?). We still hold in IRA. Selling for a loss, if extant in IRA, does no good tax-wise.

[H2R]

I sold all my shares. With a loss. Arggg.
I woke up early but had a call with India, so did not see the news until now...
This SUCKS! For me and for ALS patients.

[north40000]

I see the West Coast has awakened. For us, we still have a good LTCG...better than avg., and in a company with more in pipeline.

Any catalysts in next year?, or will CYTK be trading fodder for awhile, with better opportunities elsewhere?

[H2R]

This SUCKS!!!

[north40000]

https://ih.advfn.com/p.php?pid=nmona&article=76140123

http://ih.advfn.com/p.php?pid=nmona&article=76140679

Wife went to work, now I can post a link or 2, fwiw + some text from PR:


Cytokinetics Announces Negative Results From VITALITY-ALS

Today : Tuesday 21 November 2017




Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS), the international Phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis (ALS), did not meet the primary endpoint of change from baseline in slow vital capacity (SVC) which was evaluated at 24 weeks following randomization or any of the secondary endpoints in the trial which were evaluated at 48 weeks.

No new safety or tolerability findings related to tirasemtiv were identified in VITALITY-ALS. Serious adverse events were similar between patients who received tirasemtiv or placebo but more patients discontinued double-blind treatment on tirasemtiv than on placebo primarily due to non-serious adverse events related to tolerability. The decline in SVC from baseline to 24 weeks was smaller in patients who received any dose of tirasemtiv in VITALITY-ALS compared to the decline in patients receiving placebo. The largest differences from placebo were observed in patients randomized to the mid- and high-dose groups of tirasemtiv who could tolerate and remain on their target dose, although those differences were not statistically significant.

“While we are deeply disappointed by the results of VITALITY-ALS, we remain committed to people with ALS who are fighting this devastating disease and who need new therapies to slow the decline of respiratory function and muscle strength that are key hallmarks of disease progression,” said Robert I. Blum, Cytokinetics’ President and CEO. “We have decided to suspend the development of tirasemtiv. While we believe that VITALITY-ALS demonstrated pharmacologic activity for the mechanism of action, we also believe that limitations of tirasemtiv may be addressed with our next-generation fast skeletal muscle activator, CK-2127107. Based on previous Phase 1 clinical studies, we believe CK-2127107 will be better tolerated and potentially more effective than tirasemtiv in patients with ALS and look forward to Phase 2 trial results in 2018. We are grateful to the trial investigators, site personnel, patients and caregivers who participated in VITALITY-ALS.”

The results of VITALITY-ALS will be presented on December 8, 2017 at the 27th Annual International ALS/MND Symposium in Boston, MA by Jeremy Shefner, M.D., Ph.D., Lead Investigator of VITALITY-ALS, Professor and Chair of Neurology at Barrow Neurological Institute, and Professor and Executive Chair of Neurology at University of Arizona, Phoenix.

[Sugarshaker]

Trial failed ........

[north40000]

I see from scroll on TV screen, not from you, that something “sucks”—-why don’t you post a link to whatever info you have that causes the “sucks”

I suspect news that’s not good on ALS, but bad news...w/o a computer handy where I am, you have told us nothing.

My apologies—-I woke up in a bad mood. My wife is on a confidential business call in the room where my computer is located....

[Sugarshaker]

That sucks.............

[Sugarshaker]

Thanks H2R I was looking at the Dec.8 conference and the prep work for approval I guess doesn’t mean they will most likely get the nod from the FDA.

[H2R]

Hey Sugarshaker,

I just saw your post, sorry for the delay.

I would say 60-70% chances of positive news. This is just my opinion, nothing more.

Why positive? Because of slide 16 of http://ir.cytokinetics.com/static-files/6522ceaf-feee-4a48-b8dc-cb767de92a8f.

If you look at the p-values, they are pretty darn good for SVC.

And Ph III's primary endpoint is SVC.

Why only 60-70% chances?

Mostly because ALS is such a tough disease to beat. Many companies fell short in many, many clinical trials.

Anyways, I keep on hoping.

Also, if the initial indication is positive, CYTK may get some milestone payment. Not sure exactly when, but it's $100M. Not too shabby.

Best of luck!

[Sugarshaker]

H2R what is the likelihood of the phase 3 results coming out positive. I would like to buy a few more shares but having a Dec.8 conference to announce results bother me.

[H2R]

CYTK is expecting ALS Ph III in a couple of weeks. It could be a bit longer. Maybe three? Four? Not much more I gather, given the last CC.

And the stock is dropping? I hope it's not some leaks, but a continuation of the funding with little else in terms of foresight.

If ALS Ph III top line comes out positive, this should change. And I do believe that the chances for success in the VITALITY-ALS trial are good.

This ought to be an interesting month for CYTK!!!